Gaudium IVF names five markets as expansion costs persist
Key highlights
- Gaudium IVF identified Lucknow, Calcutta, Guwahati, Surat and Hyderabad for five future hubs.
- Q2 FY27 revenue rose 17.9% year on year to Rs 37.4 crore, while EBITDA was Rs 13.5 crore.
- Q2 FY27 EBITDA margin was 36%, versus 43.4% in Q2 FY26, reflecting new-hub rollout costs.
- Gaudium IVF reaffirmed Rs 130 crore FY27 revenue guidance and had nine hubs and 38 spokes at September 30, 2026.
powered by IRIS

Gaudium IVF and Women Health Limited named Lucknow, Calcutta, Guwahati, Surat and Hyderabad for five future hubs in Q2 FY27, while its EBITDA margin fell 737 basis points year on year to 36% as South Extension and Gurgaon incurred rollout costs.
Know Gaudium IVF and Women Health inside out
Results, valuation, peers and who's buying, in one view.
Which markets has Gaudium IVF selected for new hubs?
Gaudium IVF has selected five markets, Lucknow, Calcutta, Guwahati, Surat and Hyderabad, for its next hubs. Management said the locations maintain a pan-India spread, with Lucknow in the North, Calcutta and Guwahati in the East, Surat in the West and Hyderabad in the South.
The five locations form part of Gaudium IVF’s plan to open 10 centres in FY27. Management said South Extension, Gurgaon and Nagpur were the three centres already discussed under that plan, leaving seven planned centres, of which five locations had been identified and two were not named during the November 16, 2026 call.
The named markets are identified expansion locations rather than operating launches. Gaudium IVF did not disclose opening dates, facility sizes or capital expenditure for the five hubs, but said it had hired Ravish as Head of National Expansion and expected work at the identified locations to start soon.
Management linked Hyderabad to potential medical-tourism demand from the Middle East and Calcutta to potential patient flows from Bangladesh. Those comments followed management’s statement that Gaudium IVF receives patients from more than 30 countries, while the five-market plan also extends its network beyond its nine hubs as of September 30, 2026.
How far has Gaudium IVF progressed on FY27 expansion?
Gaudium IVF had opened two new hubs by the end of Q2 FY27, while a third was ready but awaiting approval. South Extension commenced operations on July 16, 2026, Gurgaon commenced on September 24, 2026, and management said Nagpur had been ready toward the end of September but could not begin operations until approval arrived.
South Extension is a 1,173-square-yard facility in South Delhi and had been operating for about 2.5 months at September 30, 2026. It includes the Gaudium Signature Lab, which combines embryology protocols with SiD for sperm assessment and ERICA for embryo evaluation, and Gaudium IVF added four spokes around the hub.
The Gurgaon hub is a 3,000-square-foot facility at Civil Lines, Gurugram, built around the same laboratory framework. Gaudium IVF added three spokes around Gurgaon, while management said patient footfalls had started there and South Extension had recorded steady growth in registrations and IVF cycles.
Gaudium IVF operated nine hubs and 38 spokes at September 30, 2026. South Extension and Gurgaon strengthen its Delhi National Capital Region network and extend its presence into Haryana, but management said their clinical teams, laboratories and premises create fixed costs before patient volumes build.
Got a follow-up? Ask IRIS
Why did Gaudium IVF’s reported margin decline?
Gaudium IVF’s reported margin declined because it absorbed pre-operational, staffing and launch costs for South Extension and Gurgaon before their volumes had fully ramped up. Consolidated earnings before interest, tax, depreciation and amortisation, or EBITDA, were Rs 13.5 crore in Q2 FY27, compared with Rs 13.8 crore in Q2 FY26, while revenue rose 17.9% to Rs 37.4 crore.
Q2 FY27 EBITDA margin was 36%, down from 43.4% a year earlier, a decline of 737 basis points. In the first half, or H1, FY27, EBITDA margin was 28%, compared with 38.3% in H1 FY26, as EBITDA fell to Rs 15.9 crore despite a 14.7% increase in revenue to Rs 56.8 crore.
Profit after tax was unchanged at Rs 9.4 crore in Q2 FY27, but its margin declined to 25.2% from 29.6% in Q2 FY26. H1 FY27 profit after tax fell to Rs 11.2 crore from Rs 12.5 crore, and the margin declined to 19.7% from 25.3%.
Management attributed the margin movement to hub rollout costs, including clinical hiring before patient volumes, and higher marketing spending at new and mature hubs. It said existing IVF-hub margins were stable, noted that Q2 FY26 had been an unusually high base, and said reported results would continue to carry early-stage rollout costs as hubs are added over the next 18 to 24 months.
What capital and timetable support Gaudium IVF’s rollout?
Gaudium IVF reported Rs 20.5 crore of cash and cash equivalents at September 30, 2026, plus Rs 39.5 crore of unutilised initial public offering proceeds held in fixed deposits. Borrowings were Rs 4.8 crore and the consolidated debt-to-equity ratio was 0.03 times, supporting management’s assessment that the expansion plan is fully funded.
Of the Rs 90 crore raised through the fresh issue, Gaudium IVF had used Rs 50.7 crore by September 30, 2026. The amount included Rs 13.5 crore for new centres, Rs 18.1 crore for repayment of borrowings, Rs 11.4 crore for general corporate purposes and Rs 7.7 crore for issue expenses; unutilised proceeds including interest earned were Rs 39.9 crore.
Management said a typical hub requires about Rs 2.5 crore of capital expenditure, including about Rs 1.5 crore for the laboratory and operating theatre, and is generally planned at around 3,000 square feet. It said new hubs have historically broken even within three to six months, while South Extension was almost at break-even within 2.5 months and Gurgaon was expected to follow a similar trajectory.
Lucknow also has a separate hospital project with a longer timetable than the FY27 hub rollout. The board approved the Gaudium Women Hospital in Lucknow in June at an estimated project cost of up to Rs 15 crore on a 30-year land lease, and management expects commercialisation in FY28-29.
Conclusion
Gaudium IVF has made its expansion programme more specific by identifying five new markets while bringing its network to nine hubs and 38 spokes at September 30, 2026. Q2 FY27 revenue increased to Rs 37.4 crore, but the rollout of South Extension and Gurgaon reduced reported EBITDA margin to 36% from 43.4% a year earlier.
The next disclosures to watch are Nagpur’s pending approval, progress on the five identified markets and the ramp-up in patient volumes at the two new hubs. Management has reaffirmed Rs 130 crore FY27 revenue guidance, expects more centres to come on stream in H2, and has scheduled the separate Lucknow hospital for commercialisation in FY28-29.


